{
    "id": 32713,
    "fullName": "FLT3 E598_Y599insFDFREYE",
    "impact": "insertion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "FLT3 E598_Y599insFDFREYE results in the insertion of seven amino acids in the Flt3 protein between amino acids 598 and 599 (UniProt.org). E598_Y599insFDFREYE has not been biochemically characterized, but can be predicted to lead to activation of Flt3 based on the effects of other Flt3 internal tandem duplication (ITD) mutations (PMID: 12970773, PMID: 9737679, PMID: 11090077).",
            "references": [
                {
                    "id": 2898,
                    "pubMedId": 11090077,
                    "title": "Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11090077"
                },
                {
                    "id": 2896,
                    "pubMedId": 12970773,
                    "title": "FLT3: ITDoes matter in leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12970773"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2897,
                    "pubMedId": 9737679,
                    "title": "Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9737679"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2322,
        "geneSymbol": "FLT3",
        "terms": [
            "FLT3",
            "CD135",
            "FLK-2",
            "FLK2",
            "STK1"
        ]
    },
    "variant": "E598_Y599insFDFREYE",
    "createDate": "03/05/2020",
    "updateDate": "03/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 188267,
        "transcript": "NM_004119",
        "gDna": "chr13:g.28034124_28034125insCTCATACTCCCTAAAGTCAAA",
        "cDna": "c.1795_1796insTTGACTTTAGGGAGTATGAGT",
        "protein": "p.E598_Y599insFDFREYE",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20799,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, B-cell acute lymphocytic leukemia cells harboring FLT3 R845G and FLT3 E598_Y599insFDFREYE were sensitive to treatment with Vanflyta (quizartinib), demonstrating decreased cell viability in culture (PMID: 30962949).",
            "molecularProfile": {
                "id": 35342,
                "profileName": "FLT3 E598_Y599insFDFREYE FLT3 R845G"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18045,
                    "pubMedId": 30962949,
                    "title": "Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20800,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, B-cell acute lymphocytic leukemia cells harboring FLT3 R845G and FLT3 E598_Y599insFDFREYE were sensitive to treatment with Crenolanib, demonstrating decreased cell viability in culture (PMID: 30962949).",
            "molecularProfile": {
                "id": 35342,
                "profileName": "FLT3 E598_Y599insFDFREYE FLT3 R845G"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 60592,
                "name": "B-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18045,
                    "pubMedId": 30962949,
                    "title": "Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962949"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35341,
            "profileName": "FLT3 E598_Y599insFDFREYE",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35342,
            "profileName": "FLT3 E598_Y599insFDFREYE FLT3 R845G",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 188267,
            "transcript": "NM_004119",
            "gDna": "chr13:g.28034124_28034125insCTCATACTCCCTAAAGTCAAA",
            "cDna": "c.1795_1796insTTGACTTTAGGGAGTATGAGT",
            "protein": "p.E598_Y599insFDFREYE",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}